Literature DB >> 26986084

Cantharidin inhibits cell proliferation and induces apoptosis through G2/M phase cell cycle arrest in hepatocellular carcinoma stem cells.

Ai-Ping Le1, Lun-Li Zhang2, Wei Liu1, Yu-Fei Shi2.   

Abstract

The present study was designed to investigate the effect of cantharidin on cell proliferation, ability of selfrenewal, cell cycle arrest and induction of apoptosis in HepG2 hepatocellular carcinoma stem cells (HCSCs). It was observed that cantharidin treatment exhibited dose- and time-dependent inhibitory effect on the viability of HCSCs. The inhibition of cell viability by cantharidin in HepG2 CD133+ and parental cells was significant at the concentration 5 and 15 µM, respectively after 48 h. Cantharidin treatment inhibited the self-renewal ability of the HCSCs and the expression of β-catenin and cyclin D1. Flow cytometry revealed that cantharidin treatment at 5 µM concentration significantly increased the cell population in G2/M phase and decreased the population in the G1 phase. Cantharidin treatment in the HCSCs for 48 h increased expression of histone H2AX, Myt1, cyclin A2, cyclin B1, p53 and cdc2 (Tyr15) phosphorylation significantly compared to the parental cells. Exposure of the HCSCs to cantharidin for 48 h at a concentration of 5 µM caused a significant increase in the proportion of apoptotic cells. Therefore, cantharidin is a promising agent for the hepatocellular carcinoma treatment.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26986084     DOI: 10.3892/or.2016.4684

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

1.  Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1.

Authors:  Galina Semenova; Dina S Stepanova; Sergey M Deyev; Jonathan Chernoff
Journal:  Biochimie       Date:  2017-01-06       Impact factor: 4.079

Review 2.  Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges.

Authors:  Kexin Li; Kunmin Xiao; Shijie Zhu; Yong Wang; Wei Wang
Journal:  Front Pharmacol       Date:  2022-05-05       Impact factor: 5.988

3.  Norcantharidin Inhibits cell growth by suppressing the expression and phosphorylation of both EGFR and c-Met in human colon cancer cells.

Authors:  Peiju Qiu; Siwen Wang; Ming Liu; He Ma; Xuan Zeng; Meng Zhang; Lingling Xu; Yidi Cui; Huixin Xu; Yang Tang; Yanli He; Lijuan Zhang
Journal:  BMC Cancer       Date:  2017-01-13       Impact factor: 4.430

Review 4.  Anticancer Attributes of Cantharidin: Involved Molecular Mechanisms and Pathways.

Authors:  Faiza Naz; Yixin Wu; Nan Zhang; Zhao Yang; Changyuan Yu
Journal:  Molecules       Date:  2020-07-19       Impact factor: 4.411

Review 5.  Recent Advances in Herbal Medicines for Digestive System Malignancies.

Authors:  Jiyao Sheng; Xiaohan Zou; Ziqian Cheng; Yien Xiang; Wei Yang; Yang Lin; Ranji Cui
Journal:  Front Pharmacol       Date:  2018-11-20       Impact factor: 5.810

6.  Methyl-Cantharidimide Inhibits Growth of Human Hepatocellular Carcinoma Cells by Inducing Cell Cycle Arrest and Promoting Apoptosis.

Authors:  Xiangzhong Huang; Wen Xie; Xiaofan Yu; Caiyun Fan; Jin Wang; Yi Cao; Jianxiang Li
Journal:  Front Oncol       Date:  2019-11-15       Impact factor: 6.244

Review 7.  Targeting the Proline-Glutamine-Asparagine-Arginine Metabolic Axis in Amino Acid Starvation Cancer Therapy.

Authors:  Macus Tien Kuo; Helen H W Chen; Lynn G Feun; Niramol Savaraj
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-18

8.  Significance of a PTEN Mutational Status-Associated Gene Signature in the Progression and Prognosis of Endometrial Carcinoma.

Authors:  Ying Wu; Jun Wang; Lina Ge; Qing Hu
Journal:  Oxid Med Cell Longev       Date:  2022-02-23       Impact factor: 6.543

9.  Cantharidin inhibits osteosarcoma proliferation and metastasis by directly targeting miR-214-3p/DKK3 axis to inactivate β-catenin nuclear translocation and LEF1 translation.

Authors:  Shaopu Hu; Junli Chang; Hongfeng Ruan; Wenlan Zhi; Xiaobo Wang; Fulai Zhao; Xiaoping Ma; Xingyuan Sun; Qianqian Liang; Hao Xu; Yongjun Wang; Yanping Yang
Journal:  Int J Biol Sci       Date:  2021-06-16       Impact factor: 6.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.